Special Issue
Topic: Drug Resistance and Cancer Stem Cell
Guest Editor(s)
Special Issue Introduction
Solid tumors as well as leukemias and lymphomas depend for their proliferation on a small group of progenitor cells, the cancer stem cells. These are tumorigenic and both self-renew and generate more differentiated, non-tumorigenic cells. The cancer stem cells are responsible for metastases, as well as for the post-therapeutic relapses of tumors. Therefore, there is a great interest and importance in identifying and, if possible, specifically targeting the cancer stem cells. Recent developments in single cell omics approaches hold great promise in this regard.
The Special Issue on "Cancer Stem Cells" will include Original Articles, Reviews, Commentaries, etc. updating the current state of knowledge and clinical uses of identifying and targeting cancer stem cells. The Special Issue will also include Research articles presenting novel outstanding data on all aspects of cancer stem cell-targeted therapies. All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.
The Special Issue on "Cancer Stem Cells" will include Original Articles, Reviews, Commentaries, etc. updating the current state of knowledge and clinical uses of identifying and targeting cancer stem cells. The Special Issue will also include Research articles presenting novel outstanding data on all aspects of cancer stem cell-targeted therapies. All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.
Keywords
Biomarkers, differentiation therapy, metastasis, omics, relapse, single cell studies, stemness
Submission Deadline
31 Aug 2019
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=245
Submission Deadline: 31 Aug 2019
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com
Chloe Yang, Assistant Editor, chloe@cdrjournal.com
Published Articles
How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance
Open Access Review 18 Mar 2020
DOI: 10.20517/cdr.2019.70
Views: Downloads:
Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype
Open Access Original Article 10 Mar 2020
DOI: 10.20517/cdr.2019.96
Views: Downloads:
Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence
Open Access Review 18 Dec 2019
DOI: 10.20517/cdr.2019.76
Views: Downloads:
Cancer stem cells in neuroblastoma therapy resistance
Open Access Review 18 Dec 2019
DOI: 10.20517/cdr.2019.72
Views: Downloads:
Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement
Open Access Review 18 Dec 2019
DOI: 10.20517/cdr.2019.56
Views: Downloads:
Computational analyses for cancer biology based on exhaustive experimental backgrounds
Open Access Review 18 Sep 2019
DOI: 10.20517/cdr.2019.33
Views: Downloads:
Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
Open Access Review 18 Sep 2019
DOI: 10.20517/cdr.2019.36
Views: Downloads: